Phase I trial enrolled 11 melanoma patients and showed promising results (Adjei et al., 2008, 142886); on this wave, phase II trials comparing selumetinib and chemotherapy (temozolomide and docetaxel) in BRAF-WT and NRAS-unselected melanoma patients were initiated. Here, NRAS is linked to melanoma.